Seagen Entered into an Exclusive Collaboration and License Agreement with Zai Lab to Develop and Commercialize Tivdak (tisotumab vedotin-tftv)
Shots:
- Seagen to receive $30.0M up front, ~$78.0M upon achievement of development & regulatory milestones, ~$185.0M upon achievement of sales milestones along with royalties on annual net sales of licensed products in the licensed territory. Both companies will share 50:50 future costs and profits, based on Aug 2017 collaboration b/w Seagen & Genmab
- Zai Lab gets an exclusive right to develop & commercialize the US FDA-approved Tivdak in Mainland China, Hong Kong, Macau & Taiwan
- The collaboration will use Zai Lab’s expertise in developing & commercializing the therapies in the licensed territory. The collaboration also supports patient enrollment for the P-III (InnovaTV 301) trial of Tivdak in recurrent or metastatic cervical cancer
Ref: Businesswire | Image: Seagen
Click here to read the full press release
Tags
[11:39] Neha Madan Seagen Entered into an Exclusive Collaboration and License Agreement with Zai Lab to Develop and Commercialize Tivdak (tisotumab vedotin-tftv) Shots: Seagen to receive $30.0M up front
~$185.0M upon achievement of sales milestones along with royalties on annual net sales of licensed products in the licensed territory. Both companies will share 50:50 future costs and profits
based on Aug 2017 collaboration b/w Seagen & Genmab Zai Lab gets an exclusive right to develop & commercialize the US FDA-approved Tivdak in Mainland China
Cancer like 1 Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv) Seagen Inc.
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
